Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00644969 · ClinicalTrials.gov registry record · Phase 3
Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 128
- Enrollment target
NCT00644969 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 128 participants.
The verdict
NCT00644969, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 128 participants
- Enrollment target
Study Summary
Study will determine whether patients with schizophrenia or schizoaffective disorder can be helped to quit smoking safely while using varenicline and receiving smoking cessation counseling.
Interventions
- DRUG placebo
- DRUG varenicline (CP-526,555)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00644969
The ClinicalTrials.gov registry entry for NCT00644969 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00644969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00644969 about?
NCT00644969 is a clinical study titled "Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder". Study will determine whether patients with schizophrenia or schizoaffective disorder can be helped to quit smoking safely while using varenicline and receiving smoking cessation counseling.
What is the current status of trial NCT00644969?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 128 participants. The study started on 2008-05. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00644969?
The interventions under investigation include: placebo (DRUG), varenicline (CP-526,555) (DRUG).
Who is sponsoring clinical trial NCT00644969?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.